RPL35A是參與胃癌發生發展的關鍵啟動子

2021年9月，中國人民解放軍總醫院**醫療中心普外科高級科(Senior Department of General Surgery, The First Medical Center of Chinese, PLA General Hospital, Fuxin Road, No. 28, Haidian District,Beijing 100853, China) Canrong Lu老師研究團隊在《Cancer Cell International》上發表論文：

“RPL35A is a key promotor involved in the development and progression of gastric cancer”

“RPL35A是參與胃癌發生發展的關鍵啟動子”

Abstract：

Background: RPL35A has been reported to work as a biomarker in tumor angiogenesis. However, little work has been performed on the expression level and functional importance of RPL35A in gastric cancer (GC).

Methods: The protein expression level of RPL35A was detected by immunohistochemical staining and western blot analysis. The Celigo cell counting assay was used to assess cell proliferation. Both the wound healing assay and the transwell assay were conducted to evaluate cell migration. Flow cytometric analysis was utilized to detect cell apoptosis and cell cycle. A mouse xenograft model was constructed for in vivo experiments.

Results: The results demonstrated that RPL35A expression was abundantly up-regulated in GC and positively related to tumor infiltrate. In addition, RPL35A knockdown could significantly suppress cell proliferation, migration, enhance apoptosis and arrest cell cycle. The in vivo study also verified the inhibitory effects of RPL35A knockdown on GC tumorigenesis.

Conclusions: The above mentioned results indicated that the knockdown of RPL35A might be a considerable therapeutic strategy for the treatment of gastric cancer.

摘要：

背景:RPL35A已被報道為腫瘤血管生成的生物標志物。然而，關于RPL35A在胃癌(GC)中的表達水平及其功能重要性的研究很少。

方法:采用免疫組化染色和western blot方法檢測RPL35A蛋白表達水平。采用Celigo細胞計數法評估細胞增殖情況。采用傷口愈合實驗和transwell實驗來評估細胞遷移。流式細胞術檢測細胞凋亡和細胞周期。建立小鼠異種移植物模型進行體內實驗。

結果:結果顯示RPL35A在胃癌中表達量顯著上調，與腫瘤浸潤呈正相關。RPL35A敲低可顯著抑制細胞增殖、遷移、促進細胞凋亡、阻滯細胞周期。體內研究也證實了RPL35A敲低對GC腫瘤發生的抑制作用。

結論:上述結果提示，下調RPL35A可能是治療胃癌的一種有效的治療策略。

該論文中，AGS和MGC-803細胞的體外培養是使用Ausbian特級胎牛血清完成的。欲了解或購買Ausbian特級胎牛血清可以聯系北京締一生物400-166-8600.